Nucleic acid encoding a transdominant negative retroviral integrase

US6303334A · kind A · utility

Assignees

• WARNER-LAMBERT COMPANY LLC · US
• THE REGENTS OF THE UNIVERSITY OF MICHIGAN · US

Inventors

• Tod Holler · Ann Arbor, US
• Annette Meyer · Brighton, US
• Gary J. Nabel · Cambridge, US
• Leonard Edwin Post · Kalamazoo, US

Key dates

• Filing date: Jan 14, 1999
• Grant date: Oct 16, 2001
• Expiry date: Jan 14, 2019

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16222
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of using a transdominant negative integrase gene to make at least one cell resistant to a retroviral infection which includes retroviral infections resulting from HIV; a method for introducing a transdominant negative integrase gene into at least one mammalian cell to make said cell resistant to a retroviral infection as well as vectors, cells, and methods of constructing same useful in the afore-mentioned methods; a method of treating AIDS comprising administering to a patient an effective amount of a transdominant negative integrase gene alone or combined with agents useful for gene therapy inhibition of HIV, antiviral agents, or interleukin-2; and pharmaceutical delivery methods which include a transdominant negative integrase gene alone or combined with agents useful for gene therapy inhibition of HIV, antiviral agents, or interleukin-2.